Bevenopran structure
|
Common Name | Bevenopran | ||
|---|---|---|---|---|
| CAS Number | 676500-67-7 | Molecular Weight | 386.44500 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C20H26N4O4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of BevenopranBevenopran is a peripheral μ-opioid receptor antagonist. |
| Name | 5-[2-methoxy-4-[[2-(oxan-4-yl)ethylamino]methyl]phenoxy]pyrazine-2-carboxamide |
|---|---|
| Synonym | More Synonyms |
| Description | Bevenopran is a peripheral μ-opioid receptor antagonist. |
|---|---|
| Related Catalog | |
| Target |
μ-opioid receptor[1] |
| In Vivo | Bevenopran is a peripheral μ-opioid receptor antagonist. Bevenopran is currently under investigation for the treatment of opioid-induced bowel dysfunction (OBD)[1]. Bevenopran tends to increase bowel movement (BM) frequency, especially for 0.1 mg twice daily and 4 mg daily, respectively[1]. |
| References |
| Molecular Formula | C20H26N4O4 |
|---|---|
| Molecular Weight | 386.44500 |
| Exact Mass | 386.19500 |
| PSA | 109.58000 |
| LogP | 3.55780 |
| Storage condition | 2-8℃ |
| UNII-IC58Q2EHPJ |
| CB5945 |
| Bevenopran |